No abstract available.
Prostatic Hyperplasia*

No abstract available.
Prostatic Hyperplasia*

No abstract available.
Prostatic Hyperplasia

The study was made on 42 benign prostatic hyperplasia patients. The results showed that after one month therapy by traditional medication, symptoms scoring index IPSS reduced from 21.0 to 11.71 (p<0.05). The flow of urinary increased from 4.56ml/s to 8.98ml/s (p<0.05). Residual urine volume reduced from 16.52ml to 8.35ml (p<0.05). The therapeutic outcomes by the extract of "Than khi hoan gia giam" were classified as follows: Good in 23 cases (54.8%), Moderate in 15 cases (35.7%), Poor in 4 cases (9.5%).
Prostatic Hyperplasia ; Therapeutics ; Prostatic Hyperplasia ; Medicine, Traditional

No abstract available.
Hyperplasia* ; Prostate* ; Prostatic Hyperplasia ; Prostatic Neoplasms

The literature has suggested that alpha-receptor blockade may have therapeutic value in treating the symptoms of patients with benign prostatic hypertrophy. Terazosin is an alpha-1 adrenergic blocking agent approved by the FDA for the treatment of benign prostatic hypertrophy. We treated 30 patients with symptomatic benign prostatic hypertrophy in double- blind fashion using terazosin and placebo. In placebo group, mean total symptom score was decreased from 9.8 to 7.7 (p <0.0001), but was statistically significant in only obstructive symptom score. Changes in maximal and mean urinary flow rates were from 9.8 to 10.3 and from 4.9 to 5.3, respectively, but there was no statistical significance (p>0.05). In terazosin group, the symptom score changes in obstructive and irritative were from 6.1 to 3.3 and from 4.5 to 5.9 (p <0.0001), respectively, and changes in maximal and mean urinary flow rates were from symptoms 8.7 to 10.2 and from 4.2 to 5.9, respectively (p<0.0001). There were significant improvements in all parameters in terazosin group when compared with placebo group (p<0.05). It was concluded that terazosin is beneficial for treatment of obstructive symptoms in patients with benign prostatic hypertrophy.
Humans ; Prostatic Hyperplasia*

Background: Prostatic Specific Antigen (PSA), a helpful tumor maker in the diagnosis of prostate cancer, may rise due to many causes such as Digital Rectal Examination (DRE), Acute Urinary Retention (AUR), ect. Objective: To evaluate on the influences of some factors on the serum PSA level in Benign Prostatic Hyperplasia (BPH). Subjects and method: This study included 122 men who were diagnosed BPH with a mean age of 71.18 +/- 7.19 years (ranged 54-92). The patients were divided into 3 groups: DRE group included 60 patients, their blood samples were obtained before and after 24 hours; catheterization group included 35 patients who presented with AUR, their PSA values were determined before 48 hours and 2 weeks after elevation; the inflammation group consisted of 27 patients with symptoms of acute urinary tract infections, the PSA levels were evaluated before 48 hours and 4 weeks after anti-inflammatory therapy. Results: The PSA levels increased significantly in patients with larger prostate sizes (p<0.01, r = 0.492). PSA level tended to increase with age (p<0.05, r = 0.29). The PSA values changed 14.72 +/- 10.85% after DRE (p<0.05). After relief of urethral catheterization, PSA levels decreased 50.77 +/- 20.42% (p<0.05). After anti-inflammatory therapy, 51.59 +/- 21.87% (p<0.05). Conclusions: These results suggested that it may be the best way to perform DRE after obtaining serum PSA for analysis. Serum PSA concentration should not be determined when AUR and acute urinary tract infection.
Benign prostatic hyperplasia ; PSA

Benign Prostate Hypertrophy (BPH) is often met in men of age 40 and over and its prevalence increases with age. 128 patients with BPH diagnosis have been included in study. Diagnosis has been based on: urinary disturbances scored by American Urinary Scale, rectal examination, volume measured by ultrasound exploration, serum PSA, post-surgical gland mass weighing and pathological evaluation. Results have shown: - There is linear relationship between 2 methods of gland mass definition with r= 0.736. Thus ultrasound method can be considered as good tool for gland mass definition.- 46.8% of BPH patients have PSA value in normal range but the rest of patients have elevated PSA value. With threshold of PSA at 15ng/ml value 120/128 patients have result above that threshold. This phenomena has relation with gland mass. The average volume of those with PSA< 5ng/ml is 40.1 cm3 but reached as high as 92.5cm3 on those with PSA>15ng/ml. This correlation is very close with r=0.458.
Prostatic Hyperplasia ; Antigens

Blastolysin - hepaton - promolan is a traditional remedy to treat and prevent chorioepithelioma especially in mild and moderate cases. This remedy has been proved to apply in benign prostatic hyperplasia. Evaluation after treatment by taking drug continuously in three months: Obstacle and irritable symptoms reduce in almost patients. Volume of prostate in echography image became significantly smaller. Initial results: very good 9 cases (19.1%), good 19 cases (40.4%), moderate is 16 cases (34.0%), poor 3 cases (6.3%). This remedy is not poisonous is widely indicated and suitable for many kind of patients such as elder patients, suffering from many diseases, no indication or unwillingness for operation... It costs less than ongoing therapy. As being hypertrophy prostate is current subject, many doctors and even patients concerned with, blastolysin therapy should be studied further.
Prostatic Hyperplasia ; therapy

From 6/1981 to 6/1996 a total of 978 consecutive patients (mean age: 69) presenting with bladder outlet obstructive were admitted to Viet Duc hospital for elective transurethral resection of prostate). The feagure of TURP were increasing from year to year and the TURP/ open surgery ratio was 80% in 1996. The procedures were performed with low mortality (0.3%) and low morbidity (bleeding 0.6%, capsular perforation (0.7%). TURP syndrome (0.3%), dysuria (1.8%) incontinence (1.1%), urethral stricture (1.5%) Hospital stay: 5(2 days. Overall outcome: good: 77%, moderate 19%; unsatis factory: 4%.
Prostatic Hyperplasia ; therapy ; surgery